Lantern Pharma Announces Significant Advancement In Preclinical Synergy Of LP-184 With Checkpoint Inhibitors; To Present Data At Immuno-Oncology Summit 2024
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma has announced a significant advancement in the preclinical synergy of its drug candidate LP-184 with checkpoint inhibitors. The company plans to present this data at the Immuno-Oncology Summit 2024.
August 07, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantern Pharma has made significant progress in the preclinical synergy of its drug candidate LP-184 with checkpoint inhibitors, which will be presented at the Immuno-Oncology Summit 2024.
The announcement of significant preclinical synergy of LP-184 with checkpoint inhibitors is a positive development for Lantern Pharma. Presenting this data at a major summit could attract investor interest and potentially boost the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100